Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TREMFYA safely and effectively. See full prescribing information for TREMFYA. TREMFYA® (guselkumab) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. TREMFYA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis. TREMFYA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease.
- generic_name
- guselkumab
- product_names
- Guselkumab, guselkumab
- ndc
- 57894-640, 57894-650, 57894-651, 57894-650-01, 57894-650-02, 57894-640-01, 57894-640-04, 57894-640-11, 57894-640-99, 57894-640-03, 57894-640-06, 57894-651-01, 57894-651-02, 57894-651-04, 57894-651-11, 57894-651-22, 57894-651-99, 57894-651-92
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en